<!doctype html>
<html>

<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>The ASCO Post Timeline V1</title>

  <!-- Reset CSS styles for cross-browser consistency -->
  <link rel="stylesheet" href="css/reset.css">

  <!-- Timeline-specific styles -->
  <link rel="stylesheet" href="css/tap-timline-styles.css">

  <!-- Icons for UI elements -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.1/css/all.min.css">
</head>

<body>




  <!-- scroll container and all content : START -->

  <div class="scroll-container">
    <!-- hero : START -->

    <div class="tap-timline-top-margin"></div>

    <section id="top" class="tap-timeline-section tap-timeline-section-bg-effect center-hero-bg"
      style="background-image: url('images/1000_F_296752181_hHIEIEMQ3pIHwXCrsFTFwmcE1mfE7EIf.jpg');">

      <div class="tap-timeline-article-wrapper-hero move-article-hero-down">


<!-- mobile menu : START -->
    <div id="trigger-mobile-menu"></div>
    <div class="sticky-menu">
      <button class="tap-timeline-aside-mobile-menu">
        <i class="fa-solid fa-list"></i>
      </button>
    </div>
<!-- mobile menu : START -->

        <article class="tap-timeline-article-container fade-in-bottom">
          <h5>Historic Milestones</h5>
          <h1>HER2-Positive Metastatic Breast Cancer</h1>
          <div class="tap-timeline-hero-bar-accent"></div>
          <p>Over the past two decades, advancements in treatment options for HER2-positive metastatic breast cancer
            have
            transformed the standard of care, leading to significantly improved outcomes, extended time-to-progression,
            and
            enhanced overall survival rates. For more details, view key milestones as reported by The ASCO Post.</p>
          <a href="#item-1" class="tap-timeline-down-arrow-btn"> <i class="material-icons">arrow_downward</i></a>
        </article>
      </div>

    </section>
    <!-- hero : END -->




    <!-- timeline container : START -->
    <div class="tap-timeline-container">
      <main class="tap-timeline-main">

        <!-- item 1 : START -->
        <section id="item-1" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a13e47b0db5692e314fea5_nci-vol-10574-300_Treatment-resistant-breast-cancer-cells.jpg');">
          <div class="tap-timeline-article-wrapper">

            <article class="tap-timeline-article-container fade-in-left">
              <h5>2017</h5>
              <h2>Second-Line Therapy:</h2>
              <p>Previously, TDM-1 was the standard second-line treatment after taxane and trastuzumab. The
                <strong>EMILIA</strong> trial demonstrated TDM-1's superiority over lapatinib plus capecitabine.
              </p>
              <p class="tap-timeline-author">By Matthew Stenger</p>
              <a target="_blank" href="https://ascopost.com/News/55667" class="tap-timeline-btn">Read More <i
                  class="material-icons">arrow_forward</i></a>
            </article>
          </div>
        </section>

        <!-- item 1 : END -->

        <!-- item 2 : START -->
        <section id="item-2" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a53f9d9163ad1f93243811_AdobeStock_266980135.jpg');">
          <div class="tap-timeline-article-wrapper">

            <article class="tap-timeline-article-container fade-in-left">
              <h5>2019</h5>
              <h2>First-line Therapy (2024 Standard of Care):</h2>
              <p>The current standard front-line therapy is a combination of taxane (docetaxel or paclitaxel),
                trastuzumab,
                and pertuzumab, based on the CLEOPATRA trial results.</p>
              <p class="tap-timeline-author">By Caroline Helwick</p>
              <a target="_blank"
                href="https://ascopost.com/issues/july-10-2019/cleopatra-end-of-study-analysis-in-metastatic-breast-cancer/"
                class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
            </article>
          </div>
        </section>

        <!-- item 2 : END -->

        <!-- item 3 : START -->
        <section id="item-3" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a53ca1a27e6e25307270a3_AdobeStock_838684473.jpg');">
          <div class="tap-timeline-article-wrapper">

            <article class="tap-timeline-article-container fade-in-left">
              <h5>2020 - 2023</h5>
              <h2>Emerging Therapies:</h2>
              <p><strong>Trastuzumab Deruxtecan (T-DXd):</strong> Shown to have better progression-free survival and
                overall
                survival compared to TDM-1 in the DESTINY-Breast03 study. This therapy might move to frontline settings
                pending DESTINY-Breast09results.</p>
              <p class="tap-timeline-author">By Jo Cavallo</p>
              <a target="_blank"
                href="https://ascopost.com/issues/october-10-2021/destiny-breast03-trial-supports-second-line-use-of-t-dxd-in-metastatic-her2-positive-breast-cancer/"
                class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
              <hr>
              <p><strong>Tucatinib:</strong> Added to TDM-1 in the <strong>HER2CLIMB-02</strong> study, showed improved
                progression-free survival but did not demonstrate statistically significant overall survival benefits
                early
                on.</p>
              <p class="tap-timeline-author">By Alice Goodman</p>
              <a target="_blank"
                href="https://ascopost.com/issues/december-25-2023/tucatinib-plus-t-dm1-extends-progression-free-survival-vs-t-dm1-alone-in-advanced-her2-positive-breast-cancer/"
                class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
            </article>
          </div>
        </section>

        <!-- item 3 : END -->

        <!-- item 4 : START -->
        <section id="item-4" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a540657ccb1ad5e5b3e290_AdobeStock_907164824.jpg');">
          <div class="tap-timeline-article-wrapper">

            <article class="tap-timeline-article-container fade-in-left">
              <h5>2020 - 2023</h5>
              <h2>Post-TDM-1 Options:</h2>
              <p>T-DXd: Based on DESTINY-Breast02 results, useful after progression on TDM-1</p>
              <p class="tap-timeline-author">By Jo Cavallo</p>
              <a target="_blank"
                href="https://ascopost.com/news/april-2023/trastuzumab-deruxtecan-vs-physician-s-choice-in-her2-positive-metastatic-breast-cancer-previously-treated-with-trastuzumab-emtansine/"
                class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
              <hr>
              <p>Tucatinib plus Capecitabine: Effective per the HER2CLIMB study, especially beneficial for patients with
                brain metastases.</p>
              <p class="tap-timeline-author">By Jo Cavallo</p>
              <a target="_blank"
                href="https://ascopost.com/issues/december-25-2023/tucatinib-plus-t-dm1-extends-progression-free-survival-vs-t-dm1-alone-in-advanced-her2-positive-breast-cancer/"
                class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
            </article>
          </div>
        </section>

        <!-- item 4 : END -->

        <!-- item 5 : START -->
        <section id="item-5" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a540fe6c017a9c3f344ac6_AdobeStock_933486027.jpg');">
          <div class="tap-timeline-article-wrapper">

            <article class="tap-timeline-article-container fade-in-left">
              <h5>2020 - 2023</h5>
              <h2>Brain Metastases</h2>
              <ul>
                <li>Prevalence: Up to 50% of HER2-positive metastatic breast cancer patients develop brain metastases.
                </li>
                <li>Treatment Options: Tucatinib-based regimens are preferred for active brain metastases. T-DXd has
                  shown
                  efficacy in stable brain metastases, with ongoing studies exploring its effectiveness in active cases.
                </li>
              </ul>
              <p class="tap-timeline-author">By Matthew Stenger</p>
              <a target="_blank"
                href="https://ascopost.com/issues/digital-supplement-sabcs-meeting-highlights-2023/highlights-from-the-2023-san-antonio-breast-cancer-symposium/"
                class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
            </article>
          </div>
        </section>

        <!-- item 5 : END -->

        <!-- item 6 : START -->
        <section id="item-6" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/095675c50308f5c96c22be6d3d022fd07327c71cf9c8ff8764edc735f8d94e67_3200x1790.png.jpg');">

          <div class="tap-timeline-article-wrapper">

            <article class="tap-timeline-article-container fade-in-left">
              <h5>August 2024</h5>
              <h2>Current Practice</h2>
              <p>For first-line therapy, the standard is THP (taxane, trastuzumab, pertuzumab), followed by T-DXd if
                needed.
                For brain metastases, tucatinib-based regimens are recommended. After <strong>T-DXd</strong>, other
                options
                include TDM-1, tucatinib-based regimens, lapatinib, and various chemotherapy or endocrine therapies.
                &ldquo;HER2-positive metastatic breast cancer survival has greatly improved, shifting from the worst
                prognosis to one of the best due to targeted therapies.&rdquo;</p>
              <p class="tap-timeline-author">Sara Hurvitz</p>
              <a target="_blank"
                href="https://ascopost.com/videos/ibc-west-2024/sara-hurvitz-on-new-therapeutic-strategies-for-her2-positive-metastatic-disease-including-brain-metastases/"
                class="tap-timeline-btn"><i style="margin-right: 10px;" class="fa-solid fa-circle-play"></i> Watch
                Video</a>
            </article>
          </div>
        </section>

        <!-- item 6 : END -->

      </main>



      <!-- timeline sidebar : START -->
      <aside class="tap-timeline-aside fade-in-right">


<div class="tap-timeline-aside-inner">

        <h5>Historic Milestones</h5>
        <h3><a href="#top">HER2-Positive Metastatic Breast Cancer</a></h3>
        <!-- year 1 : START -->

        <section class="tap-timeline-aside-section">
          <div class="tap-timeline-dot-line-container"> <a href="#item-1" class="tap-timeline-aside-dot">&nbsp;</a>
            <div class="tap-timeline-aside-line"></div>
          </div>
          <div>
            <a href="#item-1" class="tap-timeline-aside-year">2017</a>
            <a href="#item-1" class="tap-timeline-aside-blurb">
              <p>Second-Line Therapy</p>
            </a>
          </div>
        </section>
        <!-- year 1 : END -->

        <!-- year 2 : START -->

        <section class="tap-timeline-aside-section">
          <div class="tap-timeline-dot-line-container"> <a href="#item-2" class="tap-timeline-aside-dot">&nbsp;</a>
            <div class="tap-timeline-aside-line"></div>
          </div>
          <div>
            <a href="#item-2" class="tap-timeline-aside-year">2019</a>
            <a href="#item-2" class="tap-timeline-aside-blurb">
              <p>Firts-Line Therapy</p>
            </a>
          </div>
        </section>
        <!-- year 2 : END -->

        <!-- year 3 : START -->

        <section class="tap-timeline-aside-section">
          <div class="tap-timeline-dot-line-container"> <a href="#item-3" class="tap-timeline-aside-dot">&nbsp;</a>
            <div class="tap-timeline-aside-line"></div>
          </div>
          <div>
            <a href="#item-3" class="tap-timeline-aside-year">2020 – 2023</a>
            <a href="#item-3" class="tap-timeline-aside-blurb">
              <p>Emerging Therapies</p>
            </a> <a href="#item-4" class="tap-timeline-aside-blurb">
              <p>Post-TDM-Options</p>
            </a> <a href="#item-5" class="tap-timeline-aside-blurb">
              <p>Brain Metastases</p>
            </a>
          </div>
        </section>
        <!-- year 3 : END -->

        <!-- year 4 : START -->

        <section class="tap-timeline-aside-section">
          <div class="tap-timeline-dot-line-container"> <a href="#item-6" class="tap-timeline-aside-dot">&nbsp;</a>
            <div class="tap-timeline-aside-line"></div>
          </div>
          <div>
            <a href="#item-6" class="tap-timeline-aside-year">2024</a>
            <a href="#item-6" class="tap-timeline-aside-blurb">
              <p>Current Practive</p>
            </a>
          </div>
        </section>
        <!-- year 4 : END -->
      </div>
      </aside>
      <!-- timeline sidebar : END -->

    </div>

    <!-- timeline container : END -->

  </div>

  <!-- scroll container and all content : END -->


  <!-- ////////// javascript docs : START ////////// -->

  <!-- timeline animation js -->

  <script src="js/timeline-animation.js"></script>

  <!-- animation fade js -->

  <script src="js/animation-fade.js"></script>


</body>

</html>